TP53 and cyclic hematopoiesis: Preclinical data suggest that continuous lenalidomide therapy leads to expansion of TP53-mutant HSCs in mice, but clinical data are limited for clonal evolution of TP53-mutant CH in patients receiving long-term lenalidomide maintenance [10].